Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $10.92

Vor Biopharma Inc. (NYSE:VORGet Free Report) has been given an average recommendation of “Buy” by the six ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $10.92.

A number of research analysts have issued reports on the stock. Barclays reduced their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a report on Friday, September 6th.

Read Our Latest Research Report on VOR

Vor Biopharma Price Performance

Shares of NYSE:VOR opened at $0.69 on Thursday. The stock’s 50-day moving average is $0.88 and its 200 day moving average is $1.28. The company has a market cap of $47.11 million, a PE ratio of -0.39 and a beta of -0.35. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $3.14.

Vor Biopharma (NYSE:VORGet Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.41). Analysts expect that Vor Biopharma will post -1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Hsbc Holdings PLC raised its stake in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Vor Biopharma during the second quarter valued at $53,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vor Biopharma in the 2nd quarter worth about $63,000. Acadian Asset Management LLC boosted its stake in Vor Biopharma by 51.4% in the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

(Get Free Report

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

Read More

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.